Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Uvadex ECP in Acute GvHD
NCT00282503Phase 3Terminated
- Sponsor
- Mallinckrodt Pharmaceuticals
- Start
- Jan 2006
- Primary completion
- Jun 2007
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of methoxsalen in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Mallinckrodt Pharmaceuticals. Primary endpoints: Complete Resolution of Acute Graft-versus-Host Disease at 8 weeks and Safety at 8 weeks. Started Jan 2006; status: terminated.
02
Drugs
methoxsalen
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT00282503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00282503.